Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

NicOx Submits NDA for Osteoarthritis Drug, But Still Seeks a Commercial Partner

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

NicOx hopes a U.S. commercial partner for naproxcinod will target primary care physicians, leaving French biotech to address specialists.

You may also be interested in...



Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?

FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.

NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By